Some of the most exciting aspects of working at 3DHEALS are discovering and meeting new startups, their founders, new visions, adjacent technologies, and the investors behind them. However, changing the world is not easy, and fundraising remains as one of many challenges founders will meet.
Since April 20th, 2018, 3DHEALS has hosted six major online and offline #Pitch3D sessions, introducing 30+ startups from all over the world to institutional investors who are interested in healthcare 3D printing, bioprinting, and adjacent fields including AI and cybersecurity (within 3D printing), 3D scanning, VR/AR, 3D Visualization, synthetic materials, and regenerative medicine. In other words, we focus on technologies that will enable decentralized and personalized healthcare a reality in our lifespan.
Online Pitch3D Startups can be within the following fields:
- Medical devices using 3D printing technologies, including but not limited to anatomical modeling, patient-specific implants, and patient-specific implantable devices
- Bioprinting and Bioprinting related applications (e.g. bio-manufactured goods and foods)
- Other emerging technologies that would improve existing digital manufacturing of medical devices (e.g. Cybersecurity, Machine learning/vision, etc.)
- Synthetic Biology
- 3D Visualization
- 3D Scanning
- Regenerative Medicine (e.g. Stem cells)
This online private event is set to be recurrent each month, aiming to create an opportunity for early-stage startups in the realm of healthcare 3D printing, bioprinting, and advanced materials to have first meetings with a curated panel institutional investors. The presentations are meant to be short (10 minutes max.) but aim to get to the bottom line quickly to stage a second 1:1 meeting that would be more in-depth and longer with interested investors. The online format also avoids the opportunity cost of the investor-startup meeting due to time and geographic barriers. To pitch in our future sessions, the application is here. To be included in our investor mailing list, you must be qualified institutional investors, please email us directly: [email protected]